To review the efficacy and toxicity of amphotericin B liposomal and various lipid formulations with conventional amphotericin B desoxycholate.
Data Sources:
Pertinent literature was identified via a MEDLINE search.
Study Selection:
English-language clinical trials.
Conclusions:
The incorporation of amphotericin B into liposomes or lipid formulations appears to be a novel method of administering amphotericin B for the treatment of serious systemic fungal infections for patients who have either failed therapy with, or are intolerant to, conventional amphotericin B desoxycholate.
Get full access to this article
View all access options for this article.
References
1.
Van EttenEWMVan de RheeNEVan KampenMBakker-WoudenbergIAJM. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother1991; 35: 2275–81.
2.
Van't WoutJWMattieHVan FurthR. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother1989; 33: 147–51.
3.
ButlerWTBennettJEAilingDWWertlakePTUtzJPHillGJ. Nephrotoxicity of amphotericin B: Early and late effects in 81 patients. Ann Intern Med1964; 61: 175–87.
4.
SchnermannJ. Regulation of single nephron filtration rate by feedback: Facts and theories. Clin Nephrol1975; 3: 75–81.
5.
MedoffGKobayashiGS. Strategies in the treatment of systemic fungal infections. N Engl J Med1980; 302: 145–55.
6.
BranchR. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med1988; 148: 2389–94.
7.
HeidemannHTGerkinsJFSpickardWAJacksonEKBranchRA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med1983; 75: 476–81.
8.
EllisWGSobelRANielsenSL. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis1982; 146: 125–37.
9.
MurrayHW. Allergic reactions to amphotericin B (letter). N Engl J Med1974; 290: 693.
Lopez-BeresteinGBodeyGFainsteinVKeatingMFrankalLSZeluffB. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med1989; 149: 2533–6.
12.
CokerRJMurphySMHarrisJRW. Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. J Antimicrob Chemother1991; 28(suppl B): 105–9.
13.
ChopraRBlairSStrangJCerviPPattersonKGGoldstoneAH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother1991; 28(supplB):93–104.
14.
RingdenOMeunierFTollemarJRicciPTuraSKuseE. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother1991; 28(suppl B): 73–82.
15.
MeunierFPrenticeHGRingenO. Liposomal amphotericin B (AmBisome): Safety data from a Phase II/III clinical trial. J Antimicrob Chemother1991; 28(suppl B): 83–91.
16.
CaillotDChavanetPCasanovasOSolaryEZanettaGBuissonM. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis1992; 11: 722–5.
17.
ChavanetPYGarryICharlierNCaillotDKistermanJPD'AthisM. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ1992; 305: 921–5.
18.
MoreauPMilpiedNFayetteNRameeJFHarousseauJL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother1992; 30: 535–41.
19.
CaillotDCasanovasOSolaryEChavanetPBonnotteBRenyG. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother1993; 31: 161–9.
20.
KanVLBennettJEAmanteaASmolskisMCMcManusEGraselaDM. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis1991; 164: 418–21.
21.
GraybillJRSharkeyPKVincentDJohnsonEHavardFan PEngR. Amphotericin B lipid complex (ABLC) in treatment (Rx) of cryptococcal meningitis (CM) in patients with AIDS (abstract 289). In: Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 29-October 2, 1991.
22.
GraselaDEchevarriaJSummerillRGonzalezDChristofaloBChangJ. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex (ABLC) or Fungizone (FZ) in adults with mucocutaneous leishmaniasis (abstract 1439). In: Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993.
23.
Llanos-CuentasACiezaJEchevarriaJChangJCamposPBernardoJ. The safety and tolerance of amphotericin B lipid complex (ABLC) vs. amphotericin B desoxycholate (Fungizone [AB]) in patients with mucocutaneous leishmaniasis (MCL) (abstract 234). In: Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11–14, 1992.
